Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549    FORM 8-K    CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 7, 2022    AIKIDO PHARMA INC. (Exact name of registrant as specified in its charter)   Delaware   000-05576   52-0849320 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)     One Rockefeller Plaza , 11th Floor , New York , NY   10020 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (703) 993-9325   N/A (Former name or former address, if changed since last report.)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   AIKI   The Nasdaq Capital Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 8.01 Other Events   On October 4, 2022, Dominari Financial Inc., a wholly owned subsidiary of AIkido Pharma Inc. (the “Company”), completed the purchase of 20% of the membership interests in Fieldpoint Private Securities, LLC, (the “Company”), a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”), otherwise pursuant to the terms of the Membership Interest Purchase Agreement, dated September 9, 2022 (“Purchase Agreement”). The second and final closing for the purchase of the balance of the membership interest in the Company will occur upon the final approval from FINRA. The complete terms of the Purchase Agreement can be found in Exhibit 2.1 of the Company’s September 9, 2022 Form 8-K, which is available online at www.sec.gov or on request from the Company.   1     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Dated: October 7, 2022 AIKIDO PHARMA INC.       By: /s/ Anthony Hayes   Name:  Anthony Hayes   Title: Chief Executive Officer     2